MXPA05008918A - Sistema de administracion transmucosal de farmacos. - Google Patents
Sistema de administracion transmucosal de farmacos.Info
- Publication number
- MXPA05008918A MXPA05008918A MXPA05008918A MXPA05008918A MXPA05008918A MX PA05008918 A MXPA05008918 A MX PA05008918A MX PA05008918 A MXPA05008918 A MX PA05008918A MX PA05008918 A MXPA05008918 A MX PA05008918A MX PA05008918 A MXPA05008918 A MX PA05008918A
- Authority
- MX
- Mexico
- Prior art keywords
- pharmaceutical agent
- lipophilic
- delivery system
- drug delivery
- dosage form
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/465—Nicotine; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Inorganic Chemistry (AREA)
- Addiction (AREA)
- Rheumatology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Zoology (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invencion describe preparaciones y formulaciones de asociaciones lipofilicas (AL) de alta actividad termodinamica, en donde hay un enlace entre un agente farmaceutico ionizable y una especie lipofilica que tiene caracteristicas ionicas opuestas a las del agente farmaceutico. Tales asociaciones lipofilicas manifiestan una alta actividad termodinamica, lo cual es evidenciado por su estado predominantemente liquido a temperatura ambiente o solvatado en un disolvente dielectrico mas bajo que el agua. Ademas, el hecho de que el agente farmaceutico este solubilizado significa que la disolucion no es una limitante para la absorcion transmucosal. Esta AL o AL-solvato se formula en una forma de dosificacion de constante dielectrica baja, en donde, despues de hidratarse, el agente farmaceutico pasa a traves del tejido mucosal hacia la circulacion sistemica. Por lo tanto, la presente invencion proporciona un sistema de distribucion transmucosal de farmacos mejorado para agentes farmaceuticos ionizables a o cerca del pH fisiologico.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US44964703P | 2003-02-24 | 2003-02-24 | |
PCT/US2004/005490 WO2004075877A1 (en) | 2003-02-24 | 2004-02-24 | Transmucosal drug delivery system |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA05008918A true MXPA05008918A (es) | 2006-02-17 |
Family
ID=32927543
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MXPA05008918A MXPA05008918A (es) | 2003-02-24 | 2004-02-24 | Sistema de administracion transmucosal de farmacos. |
Country Status (12)
Country | Link |
---|---|
US (3) | US8992974B2 (es) |
EP (3) | EP2316418A3 (es) |
JP (2) | JP5475215B2 (es) |
KR (2) | KR20120066688A (es) |
CN (1) | CN1777411B (es) |
CA (1) | CA2516816C (es) |
DK (1) | DK1599186T3 (es) |
ES (1) | ES2414084T3 (es) |
IL (1) | IL170174A (es) |
MX (1) | MXPA05008918A (es) |
RU (1) | RU2342953C2 (es) |
WO (1) | WO2004075877A1 (es) |
Families Citing this family (104)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7399488B2 (en) | 2002-07-05 | 2008-07-15 | Collegium Pharmaceutical, Inc. | Abuse-deterrent pharmaceutical compositions of opiods and other drugs |
US8840928B2 (en) | 2002-07-05 | 2014-09-23 | Collegium Pharmaceutical, Inc. | Tamper-resistant pharmaceutical compositions of opioids and other drugs |
US10004729B2 (en) | 2002-07-05 | 2018-06-26 | Collegium Pharmaceutical, Inc. | Tamper-resistant pharmaceutical compositions of opioids and other drugs |
US8557291B2 (en) | 2002-07-05 | 2013-10-15 | Collegium Pharmaceutical, Inc. | Abuse-deterrent pharmaceutical compositions of opioids and other drugs |
NO346973B1 (en) | 2002-12-20 | 2023-03-20 | Niconovum Ab | A physically and chemically stable nicotine-containing particulate material |
US9498454B2 (en) | 2003-02-24 | 2016-11-22 | Pharmaceutical Productions Inc. | Transmucosal drug delivery system |
US9358296B2 (en) | 2003-02-24 | 2016-06-07 | Pharmaceutical Productions Inc. | Transmucosal drug delivery system |
US20150080442A1 (en) * | 2003-02-24 | 2015-03-19 | Pharmaceutical Productions Inc. | Transmucosal drug delivery system |
US10172810B2 (en) * | 2003-02-24 | 2019-01-08 | Pharmaceutical Productions, Inc. | Transmucosal ketamine delivery composition |
US9254294B2 (en) | 2003-02-24 | 2016-02-09 | Pharmaceutical Productions Inc. | Transmucosal hormone delivery system |
LT1765292T (lt) | 2004-06-12 | 2018-01-10 | Collegium Pharmaceutical, Inc. | Nuo piktnaudžiavimo apsaugotos vaistų formos |
GB0416861D0 (en) * | 2004-07-29 | 2004-09-01 | Quadrant Drug Delivery Ltd | Composition |
NZ562311A (en) | 2005-04-08 | 2009-10-30 | Ozpharma Pty Ltd | Buccal delivery system |
US20060263304A1 (en) * | 2005-05-23 | 2006-11-23 | Halikas James A | Method of controlling alcohol intake and reversing alcohol effects |
WO2007011171A1 (en) * | 2005-07-21 | 2007-01-25 | Mediplex Corp. | Drug formulation containing a solubilizer for enhancing solubility, absorption, and permeability |
EP1931760A4 (en) | 2005-10-07 | 2010-10-20 | Univ Alabama | LIQUID, IONIC, MULTIFUNCTIONAL COMPOSITIONS FOR CONVICTING POLYMORPHISM AND PROVIDING BETTER PROPERTIES TO ACTIVE PHARMACEUTICAL, BIOLOGICAL, NUTRITIONAL AND ENERGY INGREDIENTS |
US9066847B2 (en) | 2007-01-05 | 2015-06-30 | Aceirx Pharmaceuticals, Inc. | Storage and dispensing devices for administration of oral transmucosal dosage forms |
US9289583B2 (en) | 2006-01-06 | 2016-03-22 | Acelrx Pharmaceuticals, Inc. | Methods for administering small volume oral transmucosal dosage forms using a dispensing device |
US8865743B2 (en) | 2006-01-06 | 2014-10-21 | Acelrx Pharmaceuticals, Inc. | Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain |
US8357114B2 (en) * | 2006-01-06 | 2013-01-22 | Acelrx Pharmaceuticals, Inc. | Drug dispensing device with flexible push rod |
US8753308B2 (en) | 2006-01-06 | 2014-06-17 | Acelrx Pharmaceuticals, Inc. | Methods for administering small volume oral transmucosal dosage forms using a dispensing device |
US8252328B2 (en) | 2006-01-06 | 2012-08-28 | Acelrx Pharmaceuticals, Inc. | Bioadhesive drug formulations for oral transmucosal delivery |
US8202535B2 (en) * | 2006-01-06 | 2012-06-19 | Acelrx Pharmaceuticals, Inc. | Small-volume oral transmucosal dosage forms |
US8252329B2 (en) | 2007-01-05 | 2012-08-28 | Acelrx Pharmaceuticals, Inc. | Bioadhesive drug formulations for oral transmucosal delivery |
US8535714B2 (en) | 2006-01-06 | 2013-09-17 | Acelrx Pharmaceuticals, Inc. | Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain |
ES2535233T3 (es) | 2006-01-25 | 2015-05-06 | Insys Therapeutics, Inc. | Pulverización de fentanilo sublingual |
EP1998748B1 (en) | 2006-03-16 | 2015-01-14 | NicoNovum AB | Improved snuff composition |
TW200815048A (en) * | 2006-06-05 | 2008-04-01 | Verus Pharmaceuticals Inc | Methods for buccal, lingual or sublingual dosing regimens of epinephrine for the treatment of allergic emergencies |
DE102006027793A1 (de) * | 2006-06-16 | 2007-12-20 | Lts Lohmann Therapie-Systeme Ag | Opioid-Kombinations-Wafer |
DE102006027790A1 (de) * | 2006-06-16 | 2007-12-20 | Lts Lohmann Therapie-Systeme Ag | Typ-2-Diabetes Kombinations-Wafer |
US20070299687A1 (en) * | 2006-06-23 | 2007-12-27 | Pamela Palmer | Inpatient system for patient-controlled delivery of oral transmucosal medications dosed as needed |
ITMI20061672A1 (it) * | 2006-09-01 | 2008-03-02 | Altergon Sa | Formulazioni di acido acetilsalicilico o suoi derivati in capsule molli,esibenti elevata stabilita' |
AU2008239683B2 (en) * | 2007-04-11 | 2014-03-27 | Pharmaceuticals Productions Inc | Melatonin tablet and methods of preparation and use |
NO2180844T3 (es) | 2007-08-02 | 2018-07-21 | ||
US20090060983A1 (en) * | 2007-08-30 | 2009-03-05 | Bunick Frank J | Method And Composition For Making An Orally Disintegrating Dosage Form |
BRPI0816890A2 (pt) * | 2007-09-18 | 2015-03-24 | Niconovum Ab | Composição de goma de mascar, uso de uma combinação de nicotina-celulose, maltitol e uma base de goma, e, método para a preparação de uma composição de goma de mascar |
MX2010004897A (es) * | 2007-10-31 | 2010-05-19 | Mcneil Ppc Inc | Forma de dosificacion oralmente desintegrada. |
EP2065038A1 (en) * | 2007-11-30 | 2009-06-03 | Pharnext | New therapeutic approaches for treating Charcot-Marie-Tooth disease |
WO2009108689A1 (en) * | 2008-02-25 | 2009-09-03 | Novavax, Inc. | Sugar glassified virus like particles (vlps) |
US20090246256A1 (en) * | 2008-03-27 | 2009-10-01 | Al-Ghananeem Abeer M | Compositions and Methods for Transmucosal Delivery of Lofexidine |
US20100022471A1 (en) * | 2008-07-23 | 2010-01-28 | Sage Products Inc. | Oral Moisturizer for Alleviating Dry Mouth |
US8833378B2 (en) * | 2008-09-17 | 2014-09-16 | Niconovum Ab | Process for preparing snuff composition |
US8945592B2 (en) | 2008-11-21 | 2015-02-03 | Acelrx Pharmaceuticals, Inc. | Sufentanil solid dosage forms comprising oxygen scavengers and methods of using the same |
RU2589837C2 (ru) * | 2009-06-05 | 2016-07-10 | Аллерган, Инк. | Искусственные слезы и терапевтические применения |
US8858210B2 (en) | 2009-09-24 | 2014-10-14 | Mcneil-Ppc, Inc. | Manufacture of variable density dosage forms utilizing radiofrequency energy |
US8871263B2 (en) | 2009-09-24 | 2014-10-28 | Mcneil-Ppc, Inc. | Manufacture of tablet in a die utilizing radiofrequency energy and meltable binder |
US20110070286A1 (en) * | 2009-09-24 | 2011-03-24 | Andreas Hugerth | Process for the manufacture of nicotine-comprising chewing gum and nicotine-comprising chewing gum manufactured according to said process |
US10668060B2 (en) | 2009-12-10 | 2020-06-02 | Collegium Pharmaceutical, Inc. | Tamper-resistant pharmaceutical compositions of opioids and other drugs |
JP6306349B2 (ja) | 2010-04-14 | 2018-04-04 | アルトリア クライアント サービシーズ リミテッド ライアビリティ カンパニー | 予成形無煙タバコ製品 |
ES2605814T3 (es) | 2011-04-29 | 2017-03-16 | Moberg Pharma Ab | Composiciones farmacéuticas que comprenden un anestésico local tal como bupivacaína para administración local en la boca o la garganta |
CN103534208B (zh) | 2011-05-13 | 2017-07-18 | 默克专利有限公司 | 无机粒子材料的制造方法 |
US10577250B2 (en) | 2011-05-13 | 2020-03-03 | Merck Patent Gmbh | Process for producing of inorganic particulate material |
KR101896441B1 (ko) * | 2011-12-21 | 2018-09-11 | 메이지 세이카 파루마 가부시키가이샤 | 국소투여형의 연하장애 개선용 의약품 |
US9233491B2 (en) | 2012-05-01 | 2016-01-12 | Johnson & Johnson Consumer Inc. | Machine for production of solid dosage forms |
US9445971B2 (en) | 2012-05-01 | 2016-09-20 | Johnson & Johnson Consumer Inc. | Method of manufacturing solid dosage form |
US20130295174A1 (en) * | 2012-05-01 | 2013-11-07 | Mcneil-Ppc, Inc. | Tablet comprising a first and second region |
US9511028B2 (en) | 2012-05-01 | 2016-12-06 | Johnson & Johnson Consumer Inc. | Orally disintegrating tablet |
SI2849730T1 (sl) | 2012-05-02 | 2017-02-28 | Orexo Ab | Novi sestavek alfentanila za zdravljenje akutne bolečine |
BR112015005878A2 (pt) * | 2012-09-17 | 2017-07-04 | Bind Therapeutics Inc | nanopartículas terapêuticas compreendendo agente terapêutico e métodos de preparar e usar as mesmas |
CA2886573C (en) * | 2012-10-11 | 2019-04-02 | Stephen Lim Chin Beng | Solid dosage form |
HUE051406T2 (hu) | 2012-11-14 | 2021-03-01 | Grace W R & Co | Biológiailag aktív anyagot és rendezetlen szervetlen oxidot tartalmazó kompozíciók |
US9352047B2 (en) | 2012-11-14 | 2016-05-31 | Abon Pharmaceuticals, Llc | Oral transmucosal drug delivery system |
US20140256766A1 (en) * | 2013-03-11 | 2014-09-11 | Pharmaceutical Productions Inc. | Transmucosal drug delivery system |
US20140256765A1 (en) * | 2013-03-11 | 2014-09-11 | Pharmaceutical Productions Inc. | Transmucosal drug delivery system |
US20140256822A1 (en) * | 2013-03-11 | 2014-09-11 | Pharmaceutical Productions Inc. | Transmucosal drug delivery system |
US10799548B2 (en) * | 2013-03-15 | 2020-10-13 | Altria Client Services Llc | Modifying taste and sensory irritation of smokeless tobacco and non-tobacco products |
CN110946867A (zh) * | 2013-04-05 | 2020-04-03 | 努梅迪公司 | 胃肠病症和其他病症的治疗 |
WO2015095644A1 (en) | 2013-12-20 | 2015-06-25 | AntiOP, Inc. | Intranasal naloxone compositions and methods of making and using same |
ES2750323T3 (es) | 2014-01-10 | 2020-03-25 | Johnson & Johnson Consumer Inc | Método para la fabricación de un comprimido mediante radiofrecuencia y partículas recubiertas con pérdida |
US10172913B2 (en) * | 2014-10-01 | 2019-01-08 | Oxytone Bioscience B.V. | Orally disintegrating solid pharmaceutical dosage unit containing a partus control substance |
US20160157515A1 (en) | 2014-12-05 | 2016-06-09 | R.J. Reynolds Tobacco Company | Smokeless tobacco pouch |
AU2015369710B2 (en) | 2014-12-23 | 2020-09-17 | Vertical Pharmaceuticals, Llc | Systems, devices and methods for dispensing oral transmucosal dosage forms |
US20180369393A1 (en) * | 2015-04-02 | 2018-12-27 | Rohm And Haas Company | Composition containing cationic hydroxyethyl cellulose |
EP3368084A4 (en) * | 2015-10-29 | 2019-07-03 | Solubest Ltd | PHARMACEUTICAL COMPOSITIONS FOR TRANSMUCOSAL RELEASE |
CN105687027A (zh) * | 2016-01-26 | 2016-06-22 | 中国科学院生物物理研究所 | 一种无醇氨基酸型免冲洗泡沫洗液 |
CN109310646A (zh) * | 2016-05-05 | 2019-02-05 | 阿奎斯蒂弗医疗股份有限公司 | 增强递送的肾上腺素组合物 |
US11273131B2 (en) | 2016-05-05 | 2022-03-15 | Aquestive Therapeutics, Inc. | Pharmaceutical compositions with enhanced permeation |
WO2017205710A1 (en) * | 2016-05-27 | 2017-11-30 | Insys Development Company, Inc. | Sublingual fentanyl formulations containing a permeation enhancer |
WO2017222575A1 (en) | 2016-06-23 | 2017-12-28 | Collegium Pharmaceutical, Inc. | Process of making more stable abuse-deterrent oral formulations |
US10493026B2 (en) | 2017-03-20 | 2019-12-03 | Johnson & Johnson Consumer Inc. | Process for making tablet using radiofrequency and lossy coated particles |
GB201709141D0 (en) | 2017-06-08 | 2017-07-26 | Klaria Pharma Holding Ab | Pharmaceutical formulation |
WO2019021476A1 (ja) * | 2017-07-28 | 2019-01-31 | 社会医療法人蘇西厚生会 まつなみリサーチパーク | アレルギー症状の予防又は治療剤 |
JP7278281B2 (ja) * | 2017-12-08 | 2023-05-19 | フェルティン ファルマ アー/エス | ニコチン錠 |
CN107998401B (zh) * | 2017-12-11 | 2021-06-18 | 广州立白企业集团有限公司 | 一种具有缓释效果的口腔药物制剂及其制备方法 |
WO2019182745A1 (en) | 2018-03-19 | 2019-09-26 | Bryn Pharma, LLC | Epinephrine spray formulations |
GB201808462D0 (en) | 2018-05-23 | 2018-07-11 | Klaria Pharma Holding Ab | Pharmaceutical formulation |
US10653690B1 (en) * | 2019-07-09 | 2020-05-19 | Orexo Ab | Pharmaceutical composition for nasal delivery |
WO2021026330A1 (en) * | 2019-08-06 | 2021-02-11 | Bryn Pharma, LLC | Methods, devices, and systems for administered epinephrine |
US11872231B2 (en) | 2019-12-09 | 2024-01-16 | Nicoventures Trading Limited | Moist oral product comprising an active ingredient |
US11883527B2 (en) | 2019-12-09 | 2024-01-30 | Nicoventures Trading Limited | Oral composition and method of manufacture |
US11672862B2 (en) | 2019-12-09 | 2023-06-13 | Nicoventures Trading Limited | Oral products with reduced irritation |
US11617744B2 (en) | 2019-12-09 | 2023-04-04 | Nico Ventures Trading Limited | Moist oral compositions |
US11826462B2 (en) | 2019-12-09 | 2023-11-28 | Nicoventures Trading Limited | Oral product with sustained flavor release |
US11793230B2 (en) | 2019-12-09 | 2023-10-24 | Nicoventures Trading Limited | Oral products with improved binding of active ingredients |
US11889856B2 (en) | 2019-12-09 | 2024-02-06 | Nicoventures Trading Limited | Oral foam composition |
MX2022007013A (es) | 2019-12-09 | 2022-09-07 | Nicoventures Trading Ltd | Producto oral que comprende un canabinoide. |
US11969502B2 (en) | 2019-12-09 | 2024-04-30 | Nicoventures Trading Limited | Oral products |
KR102291180B1 (ko) * | 2019-12-18 | 2021-08-18 | 충남대학교산학협력단 | 구강내 속붕해 필름형 제제 및 이의 제조방법 |
US11712059B2 (en) | 2020-02-24 | 2023-08-01 | Nicoventures Trading Limited | Beaded tobacco material and related method of manufacture |
CN115666513A (zh) | 2020-05-18 | 2023-01-31 | 奥瑞克索股份公司 | 用于药物递送的新颖药物组合物 |
US20220087998A1 (en) * | 2020-09-23 | 2022-03-24 | New Perception Research Pharmaceuticals L.L.C. | Pharmaceutical drug therapy for autism |
US11839602B2 (en) | 2020-11-25 | 2023-12-12 | Nicoventures Trading Limited | Oral cannabinoid product with lipid component |
WO2022157564A1 (en) * | 2021-01-23 | 2022-07-28 | Cellix Bio Private Limited | A pharmaceutical composition comprising famotidine, lidocaine and melatonin |
EP4236921A1 (en) | 2021-11-25 | 2023-09-06 | Orexo AB | Pharmaceutical composition comprising adrenaline |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5132114A (en) | 1985-05-01 | 1992-07-21 | University Of Utah Research Foundation | Compositions and methods of manufacture of compressed powder medicaments |
US4816247A (en) | 1985-09-11 | 1989-03-28 | American Cyanamid Company | Emulsion compositions for administration of sparingly water soluble ionizable hydrophobic drugs |
US4753800A (en) * | 1985-10-04 | 1988-06-28 | Warner-Lambert Company | Medicament adsorbates and their preparation |
IT1227626B (it) | 1988-11-28 | 1991-04-23 | Vectorpharma Int | Farmaci supportati aventi velocita' di dissoluzione aumentata e procedimento per la loro preparazione |
WO1990009385A1 (en) * | 1989-02-17 | 1990-08-23 | The Liposome Company, Inc. | Lipid excipient for nasal delivery and topical application |
DE3908047A1 (de) | 1989-03-13 | 1990-09-20 | Desitin Arzneimittel Gmbh | Hochdisperse pharmazeutische zusammensetzung |
US5374645A (en) | 1990-01-22 | 1994-12-20 | Ciba-Geigy Corporation | Transdermal administation of ionic pharmaceutically active agents via aqueous isopropanol |
AU1252692A (en) | 1991-03-04 | 1992-10-06 | Warner-Lambert Company | Novel salts/ion pairs of non-steroidal anti-inflammatory drugs in various dosage forms |
US5135753A (en) * | 1991-03-12 | 1992-08-04 | Pharmetrix Corporation | Method and therapeutic system for smoking cessation |
US5549906A (en) | 1993-07-26 | 1996-08-27 | Pharmacia Ab | Nicotine lozenge and therapeutic method for smoking cessation |
US5479540A (en) * | 1994-06-30 | 1995-12-26 | The Whitaker Corporation | Passively aligned bi-directional optoelectronic transceiver module assembly |
IT1274034B (it) | 1994-07-26 | 1997-07-14 | Applied Pharma Res | Composizioni farmaceutiche a base di gomma da masticare e procedimento per la loro preparazione |
JPH08277216A (ja) * | 1995-02-09 | 1996-10-22 | Makoto Otsuka | 粉末剤および薬物の放出速度制御方法 |
US5800834A (en) * | 1996-06-10 | 1998-09-01 | Spireas; Spiridon | Liquisolid systems and methods of preparing same |
JP2000505090A (ja) * | 1996-07-11 | 2000-04-25 | ファーマーク、ニーダーランド、ベスローテン、フェンノートシャップ | インドール選択的セロトニンアゴニストを含む包接錯体 |
US6395713B1 (en) | 1997-07-23 | 2002-05-28 | Ribozyme Pharmaceuticals, Inc. | Compositions for the delivery of negatively charged molecules |
US6630498B2 (en) | 1997-08-06 | 2003-10-07 | Smithkline Beecham Corporation | Eprosartan arginyl charge-neutralization-complex and a process for its preparation and formulation |
SE9703458D0 (sv) * | 1997-09-25 | 1997-09-25 | Pharmacia & Upjohn Ab | Nicotine compositions and methods of formulation thereof |
NZ502878A (en) * | 1997-10-03 | 2002-03-01 | Warner Lambert Co | Compressed nitroglycerin tablet containing glyceryl monstearate as a stabilizer |
IL122084A (en) * | 1997-10-31 | 1999-09-22 | Lurident Ltd | Formulation for personal care with mucoadhesive properties |
US6248760B1 (en) | 1999-04-14 | 2001-06-19 | Paul C Wilhelmsen | Tablet giving rapid release of nicotine for transmucosal administration |
WO2001022937A1 (en) | 1999-09-27 | 2001-04-05 | Sonus Pharmaceuticals, Inc. | Compositions of tocol-soluble therapeutics |
US6264981B1 (en) | 1999-10-27 | 2001-07-24 | Anesta Corporation | Oral transmucosal drug dosage using solid solution |
US6495154B1 (en) * | 2000-11-21 | 2002-12-17 | Vivus Inc. | On demand administration of clomipramine and salts thereof to treat premature ejaculation |
NZ527113A (en) * | 2001-02-08 | 2005-04-29 | Pharmacia Corp | Rapid-onset medicament for the treatment of sexual dysfunction |
DE10153078A1 (de) * | 2001-10-30 | 2003-05-22 | Degussa | Verwendung von Granulaten auf Basis von pyrogen hergestelltem Siliciumdioxid in pharmazeutischen Zusammensetzungen |
SE0104388D0 (sv) | 2001-12-27 | 2001-12-27 | Pharmacia Ab | New formulation and use and manufacture thereof |
IL164163A0 (en) * | 2002-04-09 | 2005-12-18 | Pharmacia Corp | Process for preparing a finely self-emulsifiable pharmaceutical composition |
-
2004
- 2004-02-24 DK DK04714139.5T patent/DK1599186T3/da active
- 2004-02-24 WO PCT/US2004/005490 patent/WO2004075877A1/en active Application Filing
- 2004-02-24 US US10/545,774 patent/US8992974B2/en active Active
- 2004-02-24 RU RU2005130013/15A patent/RU2342953C2/ru active
- 2004-02-24 KR KR1020127014734A patent/KR20120066688A/ko not_active Application Discontinuation
- 2004-02-24 CN CN2004800106000A patent/CN1777411B/zh not_active Expired - Lifetime
- 2004-02-24 MX MXPA05008918A patent/MXPA05008918A/es active IP Right Grant
- 2004-02-24 KR KR1020057015592A patent/KR101170844B1/ko not_active IP Right Cessation
- 2004-02-24 EP EP10182094A patent/EP2316418A3/en not_active Withdrawn
- 2004-02-24 ES ES04714139T patent/ES2414084T3/es not_active Expired - Lifetime
- 2004-02-24 CA CA2516816A patent/CA2516816C/en not_active Expired - Lifetime
- 2004-02-24 JP JP2006503842A patent/JP5475215B2/ja not_active Expired - Lifetime
- 2004-02-24 EP EP10182127A patent/EP2343045A3/en not_active Withdrawn
- 2004-02-24 EP EP04714139.5A patent/EP1599186B1/en not_active Expired - Lifetime
-
2005
- 2005-08-09 IL IL170174A patent/IL170174A/en active IP Right Grant
-
2011
- 2011-01-12 JP JP2011004397A patent/JP2011074086A/ja active Pending
-
2015
- 2015-02-27 US US14/634,693 patent/US20150174116A1/en not_active Abandoned
-
2021
- 2021-05-03 US US17/246,852 patent/US20210251977A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20070071806A1 (en) | 2007-03-29 |
AU2004216098A1 (en) | 2004-09-10 |
EP2316418A2 (en) | 2011-05-04 |
ES2414084T3 (es) | 2013-07-18 |
JP5475215B2 (ja) | 2014-04-16 |
DK1599186T3 (da) | 2013-07-08 |
US20150174116A1 (en) | 2015-06-25 |
KR101170844B1 (ko) | 2012-08-02 |
CA2516816C (en) | 2012-02-07 |
CN1777411B (zh) | 2013-01-02 |
KR20120066688A (ko) | 2012-06-22 |
WO2004075877A1 (en) | 2004-09-10 |
EP2343045A3 (en) | 2011-09-21 |
RU2005130013A (ru) | 2006-02-10 |
KR20050120753A (ko) | 2005-12-23 |
AU2004216098A2 (en) | 2004-09-10 |
JP2011074086A (ja) | 2011-04-14 |
US20210251977A1 (en) | 2021-08-19 |
EP2343045A2 (en) | 2011-07-13 |
IL170174A (en) | 2013-11-28 |
EP1599186A1 (en) | 2005-11-30 |
RU2342953C2 (ru) | 2009-01-10 |
US8992974B2 (en) | 2015-03-31 |
CA2516816A1 (en) | 2004-09-10 |
JP2006518761A (ja) | 2006-08-17 |
EP1599186B1 (en) | 2013-04-10 |
CN1777411A (zh) | 2006-05-24 |
EP2316418A3 (en) | 2011-09-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MXPA05008918A (es) | Sistema de administracion transmucosal de farmacos. | |
MXPA05002814A (es) | Formulacion para agentes lipofilicos. | |
WO2005020962A8 (en) | Self-nanoemulsifying oily formulation for the administration of poorly water-soluble drugs | |
NZ287857A (en) | Delivery of water insoluble active agents using tocopherol as emulsifier or solvent | |
MY134422A (en) | Platinum derivative pharmaceutical formulations. | |
CY1109661T1 (el) | 5-cnac ως παραγοντας για χορηγηση απο το στομα τμηματων παραθορμονης | |
MXPA02012817A (es) | Drogas antineoplasicas liposomales y uso de las mismas. | |
WO2002087563A3 (en) | Compositions comprising an anti-microtubule agent and a polypeptide or a polysaccharide and the use thereof for the preparation of a medicament for the treatment of inflammatory conditions | |
ATE533472T1 (de) | Flüssige cannabinoid-formulierungen zur verabreichung an die schleimhäute | |
AU2001296865A1 (en) | (5-(2-hydroxy-4-chlorobenzoyl) aminovaleric acid and salts thereof and compositions containing the same for delivering active agents | |
AU7400101A (en) | Ortho-substituted anthranilic acid amides and their use as medicaments | |
MXPA05011076A (es) | Derivados de quinazolina para el tratamiento de cancer. | |
IL151311A0 (en) | Pharmaceutical compositions containing propofol | |
WO2000003753A3 (en) | Microdisperse drug delivery systems | |
TW200505452A (en) | Chemical compounds | |
NO20024194D0 (no) | Nytt selvemulgerende legemiddelavleveringssystem | |
IS2670B (is) | Bóluefni og notkun þar á til meðhöndlunar á blandaðri hreyfitaugahrörnun | |
BG106155A (en) | Novel derivatives and analogues of galanthamin | |
TW200509998A (en) | Controlled release of highly soluble agents | |
NO20043001D0 (no) | Farmasoytisk formulering omfattende cyklosporin og anvendelse derav | |
PL368686A1 (en) | Novel aminobenzoephenones | |
MXPA02008870A (es) | Novedosos antagonistas de lhrh, produccion de los mismos y sus uso como medicamentos. | |
SE0103369D0 (sv) | Pharmaceutical formulation | |
TH42244A (es) | ||
NO20013901L (no) | Umettede kolestanderivater og deres anvendelse for fremstilling av meioseregulerende medikamenter |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |